EcoDrugPlus

Phosphodiesterase 7b

Ensembl ID : ENSCSEG00000002754
Gene Symbol: PDE7B
4 Cross references
174 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSCSEG00000020701
Gene Symbol: PDE9A
1 Cross references
192 Possible Orthologues:

Phosphoinositide 3-Kinase Regulatory Subunit 5-Like

Ensembl ID : ENSCSEG00000014558
Gene Symbol: LOC103393693
3 Cross references
184 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSCSEG00000013846
Gene Symbol: PIK3R1
3 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSCSEG00000001100
Gene Symbol: PIK3R3
3 Cross references
188 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSCSEG00000003615
Gene Symbol: PIK3R5
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSCSEG00000009859
Gene Symbol: PIK3R1
1 Cross references
197 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSCSEG00000021209
Gene Symbol: LOC103392636
3 Cross references
233 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSCSEG00000003970
Gene Symbol: GART
3 Cross references
214 Possible Orthologues:

Plasminogen

Ensembl ID : ENSCSEG00000004865
Gene Symbol: PLG
3 Cross references
255 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSCSEG00000019822
Gene Symbol: PLAT
3 Cross references
207 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSCSEG00000002801
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).